INBRX-101
- Generic Name
- INBRX-101
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein.
- Associated Conditions
- -
- Associated Therapies
- -
Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 130
- Registration Number
- NCT05897424
- Locations
- 🇦🇺
Lung Research Qld, Chermside, Queensland, Australia
Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT05856331
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇺🇸University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath